Sana Biotechnology (NASDAQ:SANA) Posts Quarterly Earnings Results

Sana Biotechnology (NASDAQ:SANA) issued its quarterly earnings data on Friday. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.01, Zacks reports.

Sana Biotechnology Price Performance

SANA stock traded down $0.11 during midday trading on Monday, hitting $2.89. The stock had a trading volume of 1,981,002 shares, compared to its average volume of 2,151,145. The firm has a market cap of $642.93 million, a PE ratio of -2.29 and a beta of 1.44. Sana Biotechnology has a 12-month low of $2.76 and a 12-month high of $12.00. The company’s 50-day moving average price is $4.21 and its 200 day moving average price is $5.77.

Insiders Place Their Bets

In other news, Director Richard Mulligan sold 150,000 shares of the business’s stock in a transaction on Tuesday, September 24th. The shares were sold at an average price of $4.08, for a total transaction of $612,000.00. Following the completion of the sale, the director now directly owns 2,848,121 shares of the company’s stock, valued at $11,620,333.68. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 31.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have recently weighed in on SANA. Citigroup increased their target price on shares of Sana Biotechnology from $8.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. JMP Securities downgraded shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. Finally, HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Sana Biotechnology in a research report on Monday.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.